LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.19 4.39

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.12

Максимум

1.19

Ключови измерители
By Trading Economics
Приходи	3.5M -20M
EPS	-0.32
Служители	49
EBITDA	6.8M -22M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+132.17% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-3.1M 71M
Предишно отваряне	-3.2
Предишно затваряне	1.19

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.06.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9.06.2026 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9.06.2026 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9.06.2026 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9.06.2026 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9.06.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9.06.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung: Additional Investment Makes It Largest Shareholder in Element

9.06.2026 г., 22:05 ч. UTC

Придобивния, сливания и поглъщания

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9.06.2026 г., 20:51 ч. UTC

Печалби

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.06.2026 г., 20:09 ч. UTC

Пазарно говорене

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9.06.2026 г., 19:36 ч. UTC

Пазарно говорене

Cattle Climbs as Crude Oil Falls -- Market Talk

9.06.2026 г., 19:32 ч. UTC

Пазарно говорене

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9.06.2026 г., 19:25 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9.06.2026 г., 19:00 ч. UTC

Пазарно говорене

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9.06.2026 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9.06.2026 г., 18:47 ч. UTC

Пазарно говорене

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9.06.2026 г., 18:37 ч. UTC

Пазарно говорене

Canada's Cooling Trade With the U.S. -- Market Talk

9.06.2026 г., 18:27 ч. UTC

Пазарно говорене

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9.06.2026 г., 17:35 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9.06.2026 г., 17:30 ч. UTC

Пазарно говорене

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9.06.2026 г., 16:34 ч. UTC

Пазарно говорене

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.06.2026 г., 15:28 ч. UTC

Пазарно говорене

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9.06.2026 г., 15:25 ч. UTC

Пазарно говорене

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

132.17% нагоре

12-месечна прогноза

Среден 2.67 USD 132.17%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.